Company Filing History:
Years Active: 2015
Title: Carmen Ubeda Perez: Innovator in Pharmaceutical Formulations
Introduction
Carmen Ubeda Perez is a notable inventor based in Cabrils, Spain. She has made significant contributions to the field of pharmaceuticals, particularly in the formulation of medications. Her innovative work has led to the development of a unique oral formulation that enhances the delivery of olanzapine, a medication used to treat various mental health conditions.
Latest Patents
Carmen holds a patent for an "Oral formulation of anhydrous olanzapine form I." This invention relates to a solid formulation for the oral administration of olanzapine, which comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof. The formulation may also include pharmaceutically acceptable excipients, with the core being coated with a functional polymer that acts as a filmogenic agent. The method for obtaining this formulation involves several steps, including providing the anhydrous olanzapine Form I, preparing a dispersion of the functional polymer, and applying this dispersion onto the solid form of olanzapine.
Career Highlights
Carmen is associated with Laboratorios Lesvi, S.L., where she continues to innovate in the pharmaceutical sector. Her work has not only contributed to the advancement of medication formulations but has also positioned her as a key player in her field. With her patent, she has demonstrated her ability to address complex challenges in drug delivery systems.
Collaborations
Carmen collaborates with talented professionals in her field, including Ignacio Diez Martin and Pablo Pablo Alba. These collaborations enhance her research and development efforts, leading to more effective pharmaceutical solutions.
Conclusion
Carmen Ubeda Perez is a pioneering inventor whose work in pharmaceutical formulations has the potential to improve patient outcomes. Her innovative approach to drug delivery exemplifies the importance of research and development in the medical field.